Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase-Reference-Cited by-同舟云学术

Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase

Published:2010-04-28 Issue:11 Volume:184 Page:5988-5998
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Frankel Timothy L.,Burns William R.,Peng Peter D.,Yu Zhiya,Chinnasamy Dhanalakshmi,Wargo Jennifer A.,Zheng Zhili,Restifo Nicholas P.,Rosenberg Steven A.,Morgan Richard A.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference50 articles.

1. Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

2. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

3. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes

4. Adoptive cell transfer: a clinical path to effective cancer immunotherapy

5. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. All-Rounder Liposomes in Cancer Immunotherapy: Strategies and Design Applications of Engineered Liposomal Nanomaterials;BioChip Journal;2024-04-03

2. Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy;Frontiers in Immunology;2024-03-13

3. Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion;Journal for ImmunoTherapy of Cancer;2022-09

4. Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells;Frontiers in Immunology;2022-07-19

5. TCR engineered T cells for solid tumor immunotherapy;Experimental Hematology & Oncology;2022-06-20